French consensus: pharmacoresistant restless legs syndrome

Chenini, S.; Arnulf, Isabelle; Monaca, C. Charley; Ghorayeb, I.

Document type :

Article dans une revue scientifique: Article de synthèse/Review paper

DOI :

10.1016/j.neurol.2018.06.003

PMID :

30075957

Permalink :

http://hdl.handle.net/20.500.12210/15927

Title :

French consensus: pharmacoresistant restless legs syndrome

Author(s) :

Chenini, S. [Auteur]
Arnulf, Isabelle [Auteur]
Monaca, C. Charley [Auteur]
Ghorayeb, I. [Auteur]

Journal title :

Revue neurologique

Abbreviated title :

Rev. Neurol.

Volume number :

174

Pages :

522-531

Publication date :

2018-09-01

ISSN :

0035-3787

English keyword(s) :

Drug resistance
Willis-Ekbom syndrome
Restless legs syndrome
Opioids
Refractory

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Dopaminergic agonists, α2δ ligands and opioids are, as single-drug therapy, the first line treatment for restless legs syndrome (RLS/Willis-Ekbom disease). However, despite treatment efficacy, exacerbations of RLS may occur ...
Show more >Dopaminergic agonists, α2δ ligands and opioids are, as single-drug therapy, the first line treatment for restless legs syndrome (RLS/Willis-Ekbom disease). However, despite treatment efficacy, exacerbations of RLS may occur with overall worsening in symptoms severity, development of pain and symptoms spreading to other parts of the body, without meeting augmentation syndrome criteria. This development of "drug-resistant" RLS can cause pain, severe insomnia and psychiatric disorders that affect considerably patients' quality of life. The lack of French recommendations for this form of RLS leave physicians with few options to help patients with physical and emotional distress. Our group of neurological experts and sleep specialists proposes a diagnostic and therapeutic strategy to provide better care and appropriate treatment through searching for the organic, psychiatric and/or iatrogenic causes of drug resistance. Once a drug-resistant RLS diagnosis has been confirmed, we recommend an obligatory work-up including: a video-polysomnogram, a biological evaluation including iron status, standard numeration and C-reactive protein level. Treatment will be comorbidity-dependent: dopaminergic agonist would be recommended in case of depression or associated periodic leg movements, α2δ ligand in case of insomnia, complaint of pain, or general anxiety, in association with low-dose opioids if necessary. Strong opioids should be preferred for multiresistant RLS.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
CNRS
Inserm
Université de Lille

Collections :

Lille Neurosciences & Cognition (LilNCog) - U 1172

Research team(s) :

Troubles cognitifs dégénératifs et vasculaires

Submission date :

2019-11-27T13:02:25Z

French consensus: pharmacoresistant restless ... BibTeX CSV Excel RIS

French consensus: pharmacoresistant restless ...

BibTeX

CSV

Excel

RIS